Treatment of prediabetes

Progression of normal glucose tolerance （NGT） toovert diabetes is mediated by a transition state calledimpaired glucose tolerance （IGT）. Beta cell dysfunctionand insulin resistance are the main defects in type 2diabetes mellitus （type 2 DM） and even normoglycemicIGT patients manifest these defects....

Full description

Saved in:
Bibliographic Details
Published inWorld journal of diabetes Vol. 6; no. 12; pp. 1207 - 1222
Main Authors Kanat, Mustafa, DeFronzo, Ralph A, Abdul-Ghani, Muhammad A
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 25.09.2015
Subjects
2diabetes
Diabetes
fasting
glucose
glucose;Impared
Impaired
mellitus
Prediabetes
prevention
Review
tolerance
Type
Impared glucose tolerance
Impaired fasting glucose
Type 2 diabetes mellitus
Prediabetes
Diabetes prevention
Online AccessGet full text

Cover

More Information
Summary:Progression of normal glucose tolerance （NGT） toovert diabetes is mediated by a transition state calledimpaired glucose tolerance （IGT）. Beta cell dysfunctionand insulin resistance are the main defects in type 2diabetes mellitus （type 2 DM） and even normoglycemicIGT patients manifest these defects. Beta cell dysfunctionand insulin resistance also contribute to the progressionof IGT to type 2 DM. Improving insulin sensitivity and/orpreserving functions of beta-cells can be a rational wayto normalize the GT and to control transition of IGT totype 2 DM. Loosing weight, for example, improves wholebody insulin sensitivity and preserves beta-cell functionand its inhibitory effect on progression of IGT to type 2DM had been proven. But interventions aiming weightloss usually not applicable in real life. Pharmacotherapyis another option to gain better insulin sensitivity andto maintain beta-cell function. In this review, twopotential treatment options （lifestyle modification andpharmacologic agents） that limits the IGT-type 2 DMconversion in prediabetic subjects are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Correspondence to: Dr. Mustafa Kanat, MD, Division of Diabetes, Department of Internal Medicine, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214 Istanbul, Turkey. mustafa.kanat@gmail.com
Telephone: +90-542-3131400
Author contributions: All authors contributed to this manuscript.
ISSN:1948-9358
1948-9358
DOI:10.4239/wjd.v6.i12.1207